循环T细胞增强抗PD-1和乐伐替尼的疗效。
Circulating T cells fuel anti-PD-1 and lenvatinib efficacy.
作者信息
Matulich Peter J, Burger Megan L
机构信息
Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA; Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
出版信息
Cancer Cell. 2025 Feb 10;43(2):173-175. doi: 10.1016/j.ccell.2024.12.003. Epub 2025 Jan 30.
The mechanisms underlying synergy between checkpoint blockade and anti-angiogenic therapy remain elusive. In this issue of Cancer Cell, Guo et al. analyze hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8 T cell population critical for treatment efficacy. Engaging these cells could enhance immunotherapy across other settings.
检查点阻断疗法与抗血管生成疗法之间协同作用的潜在机制仍不清楚。在本期《癌细胞》杂志中，郭等人分析了接受抗PD-1和乐伐替尼治疗的肝细胞癌患者，确定了一个对治疗效果至关重要的循环CD8 T细胞群体。激活这些细胞可能会增强其他情况下的免疫治疗效果。
Zotero 插件